Scientists use gene transfer technology and common virus to block neuropathic pain in animals
Remember how it felt the last time you burned your finger on a hot stove? Imagine what it's like to have that burning pain in your hands or feet all the time and know there's virtually nothing you can do about it. David Fink, M.D.It's called
neuropathic pain, and it's a common complication of many diseases and medical conditions, especially diabetes. Drugs have little effect on this type...
Scientists use gene transfer technology and common virus to block neuropathic pain
Remember how it felt the last time you burned your finger on a hot stove? Imagine what it's like to have that burning pain in your hands or feet all the time and know there's virtually nothing you can do about it. It's called
neuropathic pain, and it's a common complication of many diseases and medical conditions, especially diabetes. Drugs have little effect on this type of pain, which is...
Expert Opinion Highlights Avigen's AV411 as Potential New
Therapeutic for Neuropathic Pain and Opioid Withdrawal
Focus On AV411's Unique Mechanism of Action and Broad Potential forthe Treatment of Neurological Conditions ALAMEDA, Calif., June 26, 2007 (PRIME NEWSWIRE) -- Avigen, Inc.(Nasdaq:AVGN), a biopharmaceutical company innovating therapeuticsfor the treatment of neurological conditions, announced today thatExpert Opinion on Investigational Drugs has published an articlefeaturing...
AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic
Peripheral Neuropathic Pain at International Congress on
Neuropathic Pain
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - AVANIRPharmaceuticals (NASDAQ:AVNR) today announced the presentation ofPhase III data, including efficacy, safety and improvements inpatient-centered outcomes in patients with diabetic peripheral
neuropathic (DPN) pain treated with the investigational drugZenvia(TM) (dextromethorphan/quinidine (DM/Q)), an NMDA receptorantagonist and sigma-1...
NeurogesX Announces Presentation of Positive Phase 3 Clinical Data
at the Second International Congress on Neuropathic Pain Meeting
(NeuPSIG)
SAN CARLOS, Calif., June 07, 2007 /PRNewswire-FirstCall/ --NeurogesX, Inc. announced today the presentation of clinical datafrom a positive Phase 3 trial in postherpetic neuralgia (PHN).Misha-Miroslav Backonja, M.D., Professor of Neurology at Universityof Wisconsin in Madison and lead academic investigator in theNeurogesX trial, plans to present the results of the study in aJune 8 poster...
AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic
Peripheral Neuropathic Pain at Second International Congress on
Neuropathic Pain
ALISO VIEJO, Calif.--(BUSINESS WIRE)--May 8, 2007 - AVANIRPharmaceuticals (NASDAQ:AVNR) today announced Phase III data on theefficacy, safety and improvements in patient-centered outcomes inpatients with diabetic peripheral
neuropathic (DPN) pain treatedwith the investigational drug Zenvia(TM) (dextromethorphan /quinidine) will be presented in two scientific posters at theSecond Internation...
Cephalon Presents Positive Results for Fentora in Breakthrough Pain
Associated with Neuropathic Conditions
All Efficacy Measures Reached Statistical Significance FRAZER, Pa., May 01, 2007 /PRNewswire-FirstCall/ -- A Cephalon,Inc. Phase 3 clinical trial presented today at the 59th AnnualMeeting of the American Academy of Neurology in Boston highlightsdata demonstrating that FENTORA(R) (fentanyl buccal tablet) [C-II]is beneficial for the treatment of breakthrough pain in patientswith...
More>>